Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Inclusion Criteria: * Provide written informed consent. * Has a diagnosis of true or functional iron deficiency without anemia within 30 days of treatment on this protocol * Iron deficiency without anemia (normal Hgb \>/= 11.6 g/dL but ferritin \< 30 ng/mL) * Functional iron deficiency without anemia (ferritin \>30 ng/ml and iron saturation of \<50%) * Has a clinical diagnosis of suspected epithelial ovarian cancer based on imaging studies, exam findings and laboratory values * Participants must be planning to receive neoadjuvant chemotherapy for their cancer diagnosis (NACT is defined as chemotherapy prior to debulking surgery) * Participants must be planning to undergo surgery for their cancer diagnosis * Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to administration of first dose of IV iron sucrose. WOCBP is defined as patients who retain their reproductive structures and are not menopausal (defined as \> age 50 with no menses for at least 1 year) * Participants of reproductive potential must agree to use effective birth control during study participation. Effective birth control is defined as any FDA approved contraceptive method Exclusion Criteria: * Currently taken any form of oral or intravenous iron therapy. Patients must have discontinued iron therapy \> 30 days from study entry * Current untreated or unstable heart disease * History of iron induced hypersensitivity or allergy * History of leukemia, ly…